Executive Summary
The quality of plasmid DNA used as a starting material is a foundational variable in the success of gene editing and gene therapy programs. Contaminants and batch-to-batch inconsistencies in plasmid preparations introduce significant risks, potentially confounding preclinical data and jeopardizing IND submissions. A strategy built on high-purity, well-characterized plasmid DNA minimizes these risks, ensuring that in vivo outcomes are a direct result of the therapeutic construct, not the manufacturing inputs. This approach is fundamental to achieving a predictable 18-24 month timeline to IND.
Frequently Asked Questions
Q: How does plasmid DNA purity impact IND-enabling toxicology studies for CRISPR therapies?
Plasmid DNA purity directly affects the safety profile observed in IND-enabling toxicology studies. Residual contaminants such as endotoxins or host cell proteins can elicit unintended immune responses or cellular toxicity, confounding the interpretation of the therapeutic’s own safety profile. Using high-purity plasmid for vector production ensures that any adverse findings are attributable to the nuclease or vector, not the manufacturing artifacts.
Q: What are the key CMC considerations for plasmid DNA used in dual-AAV vector systems?
For dual-AAV vector systems, which require co-administration of two distinct vectors, CMC for the input plasmids is magnified. Key considerations include ensuring exceptional batch-to-batch consistency in purity, concentration, and supercoiled-to-open-circular ratio for both plasmid preparations. This consistency is vital for maintaining a fixed stoichiometric ratio of the expressed components in vivo, which is directly linked to therapeutic efficacy and safety.
Q: Can a single scientific team manage both plasmid production and subsequent GxP in vivo investigations?
Yes, integrating plasmid production with GxP-compliant in vivo investigations within a single operational framework reduces logistical friction and mitigates timeline risk. This model provides a continuous chain of custody and data integrity from the starting material to the final toxicology report, supported by our >100,000 sq ft of integrated laboratory and vivarium space `
`.
The fidelity of advanced nuclease platforms like CRISPR-Cas9, base editors, and prime editors is directly dependent on the quality of the plasmid DNA templates used to produce them. Beyond simple sequence verification, the absence of process-related impurities is a determining factor in preclinical performance and regulatory acceptance.
Contaminants inherent to standard plasmid preparations can obscure the true biological activity of a gene editing therapeutic. These impurities can trigger innate immune responses or introduce confounding variables that make it difficult to isolate the true safety and efficacy profile of the asset during IND-enabling toxicology investigations.
The Strategic Value of Plasmid Consistency
For complex therapeutic strategies, the requirement for plasmid quality is amplified. Gene targeting approaches that utilize dual-AAV vector systems to deliver separate components of a nuclease platform (PMID: 32095520) depend on the consistent, stoichiometric expression of each part. Variability in the quality of the two input plasmids can disrupt this balance, leading to inconsistent editing efficiency and unpredictable outcomes.
A well-defined and reproducible plasmid manufacturing process provides the foundation for a robust data package. This was demonstrated in a canine model of MPS I, where the ability to accurately evaluate therapeutic efficacy and determine a minimum effective dose was contingent on using a highly pure AAV vector, free from confounding variables (PMID: 27386755). The quality of the data from such preclinical models is only as reliable as the quality of the materials administered.
Our approach to plasmid production is integrated within our broader Vector | CMC | Analytics Services. This ensures that the materials used for vector production meet the rigorous standards required for GxP-compliant preclinical programs. This integrated strategy is a core component of the operational expertise that has enabled our core scientific leadership and principal scientists to achieve a 100% successful IND rate since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.
Featured Video: Franklin BioLab Facility Tour
This site tour showcases Franklin Biolabs’ preclinical and bioanalytical facilities, spanning >100k sq ft of animal housing and specialized laboratory space.
Watch Video Clip
